Gatien Moriceau

5.9k citations

25 papers · 2.8k indexed · 3 hit papers · h-index 21

Molecular Biology top 5%
Oncology top 2%
Immunology top 10%
Cancer Research top 5%
Computational Theory and Mathematics top 1%

Co-authors: Roger S. Lo Antoni Ribas Xiangju Kong Hubing Shi Jeffrey A. Sosman Kimberly B. Dahlman Aayoung Hong Willy Hugo
Topics: Melanoma and MAPK Pathways (15 papers)Cutaneous Melanoma Detection and Management (5 papers)Bone health and treatments (4 papers)
Cited by: Oncology Molecular Biology Cancer Research
Journals: Cell Nature Medicine Nature Communications
Partner nations: United States France Australia

In The Last Decade

Gatien Moriceau

23 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. Nature Communications profile →
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

2015 412 citations Willy Hugo, Hubing Shi et al. Cell profile →

Peers

Countries citing papers authored by Gatien Moriceau

Since Specialization

Citations

This map shows the geographic impact of Gatien Moriceau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gatien Moriceau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gatien Moriceau more than expected).

Fields of papers citing papers by Gatien Moriceau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gatien Moriceau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gatien Moriceau. The network helps show where Gatien Moriceau may publish in the future.

Co-authorship network of co-authors of Gatien Moriceau

This figure shows the co-authorship network connecting the top 25 collaborators of Gatien Moriceau. A scholar is included among the top collaborators of Gatien Moriceau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gatien Moriceau. Gatien Moriceau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors 2025 ·Immunity ·Mingming Wu,Shangfeng Yang,Zhentao Yang,(unknown),Shirley H. Lomeli,(unknown),Gatien Moriceau,(unknown),Mark C. Kelley,Carlos Prieto‐Granada,Alessio Giubellino,Mehdi Nosrati,Mohammed Kashani–Sabet,Kevin B. Kim,Douglas B. Johnson,Sixue Liu,Roger S. Lo	0
2	Multi-organ landscape of therapy-resistant melanoma 2023 ·Nature Medicine ·Sixue Liu,(unknown),Shirley H. Lomeli,Yan Wang,Xiao Zhang,Zhentao Yang,Raymond J. Lim,Camelia Dumitras,Philip O. Scumpia,(unknown),Gatien Moriceau,Douglas B. Johnson,Stergios J. Moschos,Roger S. Lo	20
3	Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma 2023 ·Cancer Discovery ·(unknown),Xiao Zhang,Sixue Liu,Shirley H. Lomeli,Aayoung Hong,(unknown),Zhentao Yang,(unknown),Agustin Vega-Crespo,Antoni Ribas,Stergios J. Moschos,Gatien Moriceau,Roger S. Lo	53
4	Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance 2022 ·Cancer Discovery ·Zhentao Yang,(unknown),Sixue Liu,Weixian Deng,Shirley H. Lomeli,Gatien Moriceau,James A. Wohlschlegel,Marco Piva,Roger S. Lo	32
5	SPRED1 deletion confers resistance to MAPK inhibition in melanoma 2020 ·The Journal of Experimental Medicine ·Julien Ablain,Sixue Liu,Gatien Moriceau,Roger S. Lo,Leonard I. Zon	21
6	Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation 2017 ·Cancer Discovery ·Chunying Song,Marco Piva,Lu Sun,Aayoung Hong,Gatien Moriceau,Xiangju Kong,Hong Zhang,Shirley H. Lomeli,Jin Qian,Clarissa C. Yu,Robert Damoiseaux,Mark C. Kelley,(unknown),Philip O. Scumpia,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Willy Hugo,Roger S. Lo	109
7	Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma 2017 ·Cancer Discovery ·Aayoung Hong,Gatien Moriceau,Lu Sun,Shirley H. Lomeli,Marco Piva,Robert Damoiseaux,Sheri L. Holmen,Norman E. Sharpless,Willy Hugo,Roger S. Lo	72
8	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction 2015 ·Cancer Cell ·Gatien Moriceau,Willy Hugo,Aayoung Hong,Hubing Shi,Xiangju Kong,Clarissa C. Yu,Richard C. Koya,Ahmed A. Samatar,Négar Khanlou,Jonathan Braun,Kathleen Ruchalski,Heike Seifert,James Larkin,Kimberly B. Dahlman,Douglas B. Johnson,Alain P. Algazi,Jeffrey A. Sosman,Antoni Ribas,Roger S. Lo	237
9	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistancebreakdown → 2015 ·Cell ·Willy Hugo,Hubing Shi,Lu Sun,Marco Piva,Chunying Song,Xiangju Kong,Gatien Moriceau,Aayoung Hong,Kimberly B. Dahlman,Douglas B. Johnson,Jeffrey A. Sosman,Antoni Ribas,Roger S. Lo	412
10	Vemurafenib resistance reprograms melanoma cells towards glutamine dependence 2015 ·Journal of Translational Medicine ·Jenny E. Hernandez‐Davies,Thai Q. Tran,Michael A. Reid,(unknown),Xazmin H. Lowman,Min Pan,Gatien Moriceau,Ying Yang,Jun Wu,Roger S. Lo,Mei Kong	91
11	Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models 2014 ·PLoS ONE ·(unknown),Gatien Moriceau,Benjamin Ory,Céline Charrier,Régis Brion,Frédéric Blanchard,Françoise Rédiní,Dominique Heymann	40
12	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapybreakdown → 2013 ·Cancer Discovery ·Hubing Shi,Willy Hugo,Xiangju Kong,Aayoung Hong,Richard C. Koya,Gatien Moriceau,Thinle Chodon,Rongqing Guo,Douglas B. Johnson,Kimberly B. Dahlman,Mark C. Kelley,Richard Kefford,Bartosz Chmielowski,John A. Glaspy,Jeffrey A. Sosman,Nicolas van Baren,Georgina V. Long,Antoni Ribas,Roger S. Lo	715
13	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition 2013 ·Cancer Discovery ·Hubing Shi,Aayoung Hong,Xiangju Kong,Richard C. Koya,Chunying Song,Gatien Moriceau,Willy Hugo,Clarissa C. Yu,Charles Ng,Thinle Chodon,Richard A. Scolyer,Richard Kefford,Antoni Ribas,Georgina V. Long,Roger S. Lo	133
14	Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors 2012 ·Cancer Discovery ·Hubing Shi,Gatien Moriceau,Xiangju Kong,Richard C. Koya,Ramin Nazarian,Gulietta M. Pupo,Antonella Bacchiocchi,Kimberly B. Dahlman,Bartosz Chmielowski,Jeffrey A. Sosman,Ruth Halaban,Richard Kefford,Georgina V. Long,Antoni Ribas,Roger S. Lo	75
15	Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistancebreakdown → 2012 ·Nature Communications ·Hubing Shi,Gatien Moriceau,Xiangju Kong,Mi‐Kyung Lee,Hane Lee,Richard C. Koya,Charles Ng,Thinle Chodon,Richard A. Scolyer,Kimberly B. Dahlman,Jeffrey A. Sosman,Richard Kefford,Georgina V. Long,Stanley F. Nelson,Antoni Ribas,Roger S. Lo	470
16	Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth 2011 ·Cancer ·Gatien Moriceau,Anke J. Roelofs,Régis Brion,Françoise Rédiní,(unknown),Michael J. Rogers,Dominique Heymann	21
17	Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process 2010 ·Cancer Research ·Gatien Moriceau,Benjamin Ory,Laura Mitrofan,Chiara Riganti,Frédéric Blanchard,Régis Brion,Céline Charrier,Séverine Battaglia,Paul Pilet,Marc G. Denis,Leonard D. Shultz,Jukka Mönkkönen,Françoise Rédiní,Dominique Heymann	74
18	Therapeutic Approach of Primary Bone Tumours by Bisphosphonates 2010 ·Current Pharmaceutical Design ·Gatien Moriceau,Benjamin Ory,(unknown),Franck Verrecchia,F. Gouin,Frédéric Blanchard,Françoise Rédiní,Dominique Heymann	30
19	Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells 2008 ·Journal of Cellular and Molecular Medicine ·Benjamin Ory,Gatien Moriceau,Valérie Trichet,Frédéric Blanchard,Martine Berreur,Françoise Rédiní,Michael J. Rogers,Dominique Heymann	27
20	mTOR Inhibitors (Rapamycin and its Derivatives) and Nitrogen Containing Bisphosphonates: Bi-Functional Compounds for the Treatment of Bone Tumours 2007 ·Current Medicinal Chemistry ·Benjamin Ory,Gatien Moriceau,Françoise Rédiní,Dominique Heymann	27

About Gatien Moriceau

Gatien Moriceau is a scholar working on Oncology, Metals and Alloys and Molecular Biology, having authored 25 papers that have together received 2.8k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (15 papers), Cutaneous Melanoma Detection and Management (5 papers) and Bone health and treatments (4 papers). The work is most often cited by research in Oncology (1.5k citations), Molecular Biology (2.2k citations) and Cancer Research (406 citations). Gatien Moriceau has collaborated with scholars based in United States, France and Australia. Frequent co-authors include Roger S. Lo, Antoni Ribas, Xiangju Kong, Hubing Shi, Jeffrey A. Sosman, Kimberly B. Dahlman, Aayoung Hong, Willy Hugo, Richard C. Koya and Douglas B. Johnson. Their work appears in journals such as Cell, Nature Medicine and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact